Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
10503 studies found for:    NCI
Show Display Options
Rank Status Study
1 Terminated Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer
Conditions: Liver Metastases;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Stage IV Colon Cancer;   Stage IV Rectal Cancer
Interventions: Drug: oxaliplatin;   Drug: capecitabine;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis
2 Not yet recruiting Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas or Diffuse Intrinsic Pontine Gliomas
Conditions: Diffuse Intrinsic Pontine Glioma;   Malignant Glioma;   Recurrent Childhood Brain Neoplasm
Interventions: Biological: Pembrolizumab;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Diffusion Weighted Imaging;   Procedure: Magnetic Resonance Spectroscopic Imaging;   Procedure: Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging;   Procedure: Perfusion Magnetic Resonance Imaging;   Procedure: Diffusion Tensor Imaging
3 Completed Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Conditions: Adult Giant Cell Glioblastoma;   Adult Glioblastoma;   Adult Gliosarcoma
Interventions: Drug: arsenic trioxide;   Radiation: radiation therapy
4 Completed
Has Results
Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Intervention: Drug: lenalidomide
5 Active, not recruiting Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: BRCA1 Mutation Carrier;   BRCA2 Mutation Carrier;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Veliparib;   Other: Laboratory Biomarker Analysis
6 Not yet recruiting Olaparib and Cediranib Maleate in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer
Conditions: Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   High Grade Ovarian Serous Adenocarcinoma;   Ovarian Endometrioid Tumor;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions: Drug: Olaparib;   Drug: Cediranib Maleate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
7 Active, not recruiting Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
Condition: Adult Solid Neoplasm
Interventions: Drug: Tivantinib;   Drug: Topotecan Hydrochloride;   Biological: Pegfilgrastim;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
8 Completed O6-benzylguanine and Carmustine in Treating Children With Refractory CNS Tumors
Condition: Brain and Central Nervous System Tumors
Interventions: Drug: O6-benzylguanine;   Drug: carmustine
9 Completed
Has Results
Everolimus in Combination With Imatinib Mesylate in Treating Patients With Locally Advanced, Locally Recurrent, or Metastatic Soft Tissue Sarcoma
Conditions: Adult Synovial Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
Interventions: Other: diagnostic laboratory biomarker analysis;   Drug: everolimus;   Drug: imatinib mesylate
10 Completed Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
Condition: Stage IIIA Non-small Cell Lung Cancer
Interventions: Drug: paclitaxel;   Drug: carboplatin;   Drug: motexafin gadolinium;   Procedure: conventional surgery;   Radiation: radiation therapy
11 Completed
Has Results
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
Conditions: Primary Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Intervention: Drug: irofulven
12 Completed
Has Results
Eflornithine and Sulindac in Preventing Colorectal Cancer in Patients With Colon Polyps
Condition: Precancerous Condition
Interventions: Other: placebo;   Drug: eflornithine;   Drug: sulindac;   Other: laboratory biomarker analysis
13 Completed Vaccine Therapy in Treating Patients With Stage IV Melanoma
Condition: Melanoma (Skin)
Interventions: Biological: dendritic cell-MART-1 peptide vaccine;   Biological: gp100 antigen;   Biological: therapeutic tumor infiltrating lymphocytes;   Biological: tyrosinase peptide
14 Terminated
Has Results
FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Mantle Cell Lymphoma
Intervention: Drug: romidepsin
15 Completed Azacitidine and Entinostat in Treating Patients With Recurrent Advanced Non-Small Cell Lung Cancer
Conditions: Recurrent Non-Small Cell Lung Carcinoma;   Stage IIIA Non-Small Cell Lung Cancer;   Stage IIIB Non-Small Cell Lung Cancer;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Entinostat;   Drug: Azacitidine;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
16 Suspended Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer
Conditions: Endometrial Clear Cell Adenocarcinoma;   Estrogen Receptor Negative;   Ovarian Clear Cell Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Recurrent Uterine Corpus Carcinoma
Interventions: Drug: Dasatinib;   Other: Laboratory Biomarker Analysis
17 Terminated
Has Results
Radiation Therapy and Stereotactic Radiosurgery With or Without Temozolomide or Erlotinib in Treating Patients With Brain Metastases Secondary to Non-Small Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer;   Tumors Metastatic to Brain
Interventions: Drug: erlotinib hydrochloride;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: stereotactic radiosurgery;   Drug: temozolomide
18 Completed Immunotoxin in Treating Patients With Leukemia or Lymphoma
Conditions: Leukemia;   Lymphoma
Intervention: Biological: LMB-2 immunotoxin
19 Recruiting Cabozantinib in Treating Younger Patients With Recurrent or Refractory Solid Tumors
Conditions: Childhood Solid Neoplasm;   Recurrent Melanoma;   Recurrent Thyroid Gland Carcinoma;   Thyroid Gland Medullary Carcinoma
Interventions: Drug: Cabozantinib S-malate;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
20 Completed Cisplatin, Irinotecan, and Bevacizumab, in Treating Patients With Small Cell Lung Cancer
Condition: Extensive Stage Small Cell Lung Cancer
Interventions: Drug: cisplatin;   Drug: irinotecan hydrochloride;   Biological: bevacizumab;   Other: laboratory biomarker analysis

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years